Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569914 | 0.93 | EGFR (0.53) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4966168 | 0.80 | ROCK1 (0.52) | CHEK2CYP4A11CYP4F2HCRTR1HCRTR2 | |
| SCHEMBL4091279 | 0.80 | EGFR (0.52) | EGFRPDE3BPDE3APDE10A | |
| SCHEMBL14489819 | 0.78 | EGFR (0.49) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1527983 | 0.77 | EGFR (0.47) | EGFRMTNR1B | |
| SCHEMBL14489815 | 0.77 | GPR119 (0.47) | EGFR | |
| Hydrochloric Acid SCHEMBL4967454 | 0.77 | EGFR (0.46) | EGFRMTNR1B | |
| SCHEMBL23379064 | 0.76 | EGFR (0.41) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5564929 | 0.76 | PIK3CD (0.51) | PIK3CDCHEK2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL5568756 | 0.76 | ERBB2 (0.47) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | EGFR 15/4885PIK3CD 294/4885CHEK2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.